Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:IMGN's Cash-to-Debt is ranked lower than
71% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NAS:IMGN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:IMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.03  Med: No Debt Max: 50356.33
Current: No Debt
2.03
50356.33
Equity-to-Asset -0.77
NAS:IMGN's Equity-to-Asset is ranked lower than
96% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:IMGN: -0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:IMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.73 Max: 0.95
Current: -0.77
-0.77
0.95
Piotroski F-Score: 3
Altman Z-Score: -1.94
Beneish M-Score: 9.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -278.94
NAS:IMGN's Operating Margin % is ranked lower than
61% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NAS:IMGN: -278.94 )
Ranked among companies with meaningful Operating Margin % only.
NAS:IMGN' s Operating Margin % Range Over the Past 10 Years
Min: -447.86  Med: -162.45 Max: -58.16
Current: -278.94
-447.86
-58.16
Net Margin % -322.31
NAS:IMGN's Net Margin % is ranked lower than
64% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:IMGN: -322.31 )
Ranked among companies with meaningful Net Margin % only.
NAS:IMGN' s Net Margin % Range Over the Past 10 Years
Min: -448.24  Med: -162.03 Max: -49.69
Current: -322.31
-448.24
-49.69
ROA % -65.79
NAS:IMGN's ROA % is ranked lower than
73% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NAS:IMGN: -65.79 )
Ranked among companies with meaningful ROA % only.
NAS:IMGN' s ROA % Range Over the Past 10 Years
Min: -48.2  Med: -36.91 Max: -21.76
Current: -65.79
-48.2
-21.76
ROC (Joel Greenblatt) % -640.59
NAS:IMGN's ROC (Joel Greenblatt) % is ranked lower than
55% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:IMGN: -640.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:IMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -649.63  Med: -383.13 Max: -150
Current: -640.59
-649.63
-150
3-Year Revenue Growth Rate 17.70
NAS:IMGN's 3-Year Revenue Growth Rate is ranked higher than
71% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:IMGN: 17.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:IMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -36.3  Med: 17.7 Max: 115.4
Current: 17.7
-36.3
115.4
3-Year EBITDA Growth Rate 19.20
NAS:IMGN's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:IMGN: 19.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:IMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -72.2  Med: 5.1 Max: 296.3
Current: 19.2
-72.2
296.3
3-Year EPS without NRI Growth Rate 24.30
NAS:IMGN's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NAS:IMGN: 24.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:IMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75.7  Med: 4.3 Max: 263.4
Current: 24.3
-75.7
263.4
GuruFocus has detected 4 Warning Signs with Immunogen Inc $NAS:IMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:IMGN's 10-Y Financials

Financials (Next Earnings Date: 2017-04-21)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

IMGN Guru Trades in Q1 2016

Ken Fisher 244,225 sh (New)
PRIMECAP Management 12,867,483 sh (unchged)
Jim Simons Sold Out
» More
Q2 2016

IMGN Guru Trades in Q2 2016

Paul Tudor Jones 63,300 sh (New)
Jim Simons 1,967,140 sh (New)
Ken Fisher 253,701 sh (+3.88%)
PRIMECAP Management 10,113,629 sh (-21.40%)
» More
Q3 2016

IMGN Guru Trades in Q3 2016

Jim Simons 2,503,340 sh (+27.26%)
Ken Fisher 253,701 sh (unchged)
PRIMECAP Management 9,619,122 sh (-4.89%)
Paul Tudor Jones 30,249 sh (-52.21%)
» More
Q4 2016

IMGN Guru Trades in Q4 2016

Paul Tudor Jones 32,880 sh (+8.70%)
Jim Simons 2,481,740 sh (-0.86%)
Ken Fisher 248,576 sh (-2.02%)
PRIMECAP Management 5,052,943 sh (-47.47%)
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AVXL, OTCPK:ELVAF, OTCPK:THERF, NAS:MNKD, NAS:IDRA, OTCPK:MXDHF, NAS:CGEN, OTCPK:CLVLF, NAS:SRNE, NAS:KMDA, NAS:MNOV, NAS:ABEO, NAS:CYAD, OTCPK:SPHRY, OTCPK:SPRWF, OTCPK:RCAR, OTCPK:VNLPY, OTCPK:OXBDF, NAS:NVLN, NAS:AUPH » details
Traded in other countries:IMU.Germany,
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: mirvetuximab soravtansine, or IMGN853, coltuximab ravtansine, formerly SAR3419, and IMGN529 and have reported preclinical data for IMGN779, which expected to be next clinical-stage compound. IMGN779 is the first ADC utilizing GN technology. The compound with ADC technology is Roche's marketed product, Kadcyla (ado-trastuzumab emtansine). Eight other ADC compounds and one non-ADC, or 'naked' antibody product candidate, are in clinical testing. The Company's current partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company, or Lilly, Novartis Institutes for BioMedical Research, Inc., or Novartis, the Roche Group, Sanofi and Takeda. Its competitors include pharmaceutical companies and other biotechnology firms, Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. Its patent portfolio had approximately 659 issued patents and approximately 645 pending patent applications all over the world. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.

Ratios

vs
industry
vs
history
PS Ratio 4.85
IMGN's PS Ratio is ranked higher than
75% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. IMGN: 4.85 )
Ranked among companies with meaningful PS Ratio only.
IMGN' s PS Ratio Range Over the Past 10 Years
Min: 2.67  Med: 14.86 Max: 97.63
Current: 4.85
2.67
97.63
EV-to-EBIT -0.56
IMGN's EV-to-EBIT is ranked lower than
99.99% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. IMGN: -0.56 )
Ranked among companies with meaningful EV-to-EBIT only.
IMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -9.1 Max: 0.1
Current: -0.56
-44
0.1
EV-to-EBITDA -0.58
IMGN's EV-to-EBITDA is ranked lower than
99.99% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. IMGN: -0.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.8  Med: -9.9 Max: 0.1
Current: -0.58
-51.8
0.1
Days Sales Outstanding 2.37
IMGN's Days Sales Outstanding is ranked higher than
95% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. IMGN: 2.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.88  Med: 18.19 Max: 88.26
Current: 2.37
2.88
88.26

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
IMGN's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. IMGN: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17  Med: -7.4 Max: -0.7
Current: -1
-17
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.33
IMGN's Price-to-Median-PS-Value is ranked higher than
91% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. IMGN: 0.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 1.2 Max: 10.58
Current: 0.33
0.22
10.58
Earnings Yield (Greenblatt) % -178.60
IMGN's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. IMGN: -178.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15095.13  Med: 0 Max: 10020.99
Current: -178.6
-15095.13
10020.99

More Statistics

Revenue (TTM) (Mil) $48.63
EPS (TTM) $ -1.80
Beta2.33
Short Percentage of Float22.85%
52-Week Range $1.51 - 9.78
Shares Outstanding (Mil)87.30

Analyst Estimate

Jun17 Jun18
Revenue (Mil $) 43 33
EPS ($) -1.31 -1.38
EPS without NRI ($) -1.31 -1.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:IMGN

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) Surge on Jan 31 2015 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
ImmunoGen 4Q Loss Misses Street Expectations Feb 20 2017
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y Feb 20 2017
Edited Transcript of IMGN earnings conference call or presentation 17-Feb-17 1:00pm GMT Feb 17 2017
ImmunoGen (IMGN) Reports Wider-than-Expected Loss Feb 17 2017
ImmunoGen Inc Earnings Call scheduled for 8:00 am ET today Feb 17 2017
Q2 2017 ImmunoGen Inc Earnings Release - 06:30 am ET Feb 17 2017
IMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 17 2017
ImmunoGen reports 2Q loss Feb 17 2017
ImmunoGen reports 2Q loss Feb 17 2017
ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended... Feb 17 2017
What's in Store for ImmunoGen (IMGN) this Earnings Season? Feb 13 2017
ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences Feb 02 2017
Immunogen Doses First Patient in Ovarian Cancer Drug Study Jan 27 2017
ImmunoGen Announces First Patient Dosed in FORWARD I Phase 3 Study of Mirvetuximab Soravtansine in... Jan 26 2017
ImmunoGen Announces Conference Call to Discuss its Results for Six-Month Period and Quarter Ended... Jan 25 2017
IMMUNOGEN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jan 23 2017
ImmunoGen Announces Departure of Sandra Poole Jan 23 2017
IMMUNOGEN INC Files SEC form 8-K, Results of Operations and Financial Condition Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)